Jpmorgan Chase & CO Maxcyte, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MXCT
# of Institutions
126Shares Held
62MCall Options Held
2.4KPut Options Held
2.1K-
Black Rock Inc. New York, NY7.23MShares$27.2 Million0.0% of portfolio
-
Cadian Capital Management, LP New York, NY6.56MShares$24.7 Million0.98% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny6.17MShares$23.2 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.35MShares$20.1 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$19 Million6.7% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $382M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...